Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody Source: Eur Respir J, 57 (5) 2002536; 10.1183/13993003.02536-2020 Year: 2021
Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Anti-CTGF antibody attenuates silica-induced lung fibrosis in rats Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018
Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018
Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Dual inhibition of Angiopoietin-2 and VEGF-A with a monoclonal antibody improves pulmonary capillary leakage in murine experimental sepsis Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure Year: 2019
The association of serum IgG antibody with symptoms of hypersensitivity pneumonitis Source: Eur Respir J 2006; 28: Suppl. 50, 675s Year: 2006
Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Efficacy of inhaled anti-IL-13 mAb in a mouse model of asthma Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011
Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies Source: International Congress 2019 – Treatment of lung cancer Year: 2019
The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma Source: Eur Respir J 2001; 18: 45-52 Year: 2001
Preclinical development of an IL-13 neutralising antibody, CAT-354, for the treatment of human asthma Source: Eur Respir J 2005; 26: Suppl. 49, 367s Year: 2005
Subcutaneuous injection of monoclonal antibody anti-DEC205 conjugated with ovalbumin atenuates allergic lung inflammation of animals previously sensitized to allergen Source: Annual Congress 2012 - Mechanisms and modulation of allergic inflammation in the lung Year: 2012
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Reversing the suppression of T-cells: the role of monoclonal antibodies Source: International Congress 2015 – Stop immune tolerance in lung cancer! Year: 2015
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena Source: Eur Respir J, 56 (4) 2000117; 10.1183/13993003.00117-2020 Year: 2020
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis Source: Eur Respir J 2016; 47:1481-1491 Year: 2016
Long-term treatment with monoclonal antibodies anti-IgE in severe asthma: Follow-up of ten patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Comparison of anti-IL-9 and anti-IL-5 treatment efficacy in a mouse model of airway eosinophilic inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 482s Year: 2003
Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019